169 results about "Beta-actin" patented technology

The invention belongs to the gene detecting technology in clinical detecting technologies of the bio-medical field and particularly relates to a kit for quickly detecting polymorphism of a human CYP2C19 gene and a using method of the kit. The kit comprises three pairs of primers, three probes, six PNA (pentose nucleic acid) sequences, a pair of beta-Actin interior label primers and an interior label probe, and further comprises a PCR (polymerase chain reaction) buffer solution of Mg<2+>, a dNTP mixture, Taq enzyme and ddH2O. The kit can be utilized to carry out qualitative detection on a polymorphic site of the CYP2C19 gene and carry out two-tube PNA-PCR fluorescent amplified reaction according to the SNP site and can carry out result judgment according to a condition whether a two-tube fluorescence curve is started or not without producing personal errors, so that a false positive rate and a false negative rate are low. And moreover, the kit can be used to realize high-flux detection easily and is capable of clinical use.

The invention belongs to the field of biochemistry, and provides a fluorescent quantitative polymerase chain reaction (PCR) kit for detecting alpha-globin gene deletion. The kit consists of a pair of specific amplified xi globin primers, a pair of specific amplified alpha1 globin primers, a pair of specific amplified alpha2 globin primers, a pair of specific amplified beta-Actin gene primers, a fluorescent probe for specifically detecting xi globin, a fluorescent probe for specifically detecting alpha1 globin, a fluorescent probe for specifically detecting alpha2 globin, a fluorescent probe for specifically detecting beta-Actin genes, a DNA polymerase and the like. The kit has good sensitivity and accuracy for detecting depletion alpha-thalassemia, has good repeatability and stability, and is totally suitable for clinical detection of alpha-thalassemia.

The invention provides a reagent for detecting a Notch signal path as well as a PCR (Polymerase Chain Reaction) detecting method and application thereof. The detecting reagent comprises PCR reaction primers for detecting an ADAM10 gene, an ADAM17 gene, an AES gene, a CBL gene, a CCND1gene, a CD44 gene, and the like, and primers of corresponding internal-reference regulatory genes GAPDH (Reduced Glyceraldehyde-Phosphate Dehydrogenase), ACTB (Beta-Actin) and B2M (Beta-2-Microglobulin). The invention provides the reagent for detecting core molecule changes of the NOTCH signal channel; by virtue of the detecting reagent, genes associated with the NOTCH channel can be quickly detected on transcriptional level by virtue of real-time fluorescent quantitative PCR; on this basis, core molecules and a mechanism of action of a tumor NOTCH signal channel are analyzed and researched, so that an NOTCH regulatory channel of tumor-associated medicaments is quickly and accurately found, and therefore, a powerful tool is provided for screening anti-tumor medicaments, discussing the mechanism of a novel targeted medicament, and the like.

The invention relates to a method of diagnosis of Huntington's Disease in a diagnostic sample of a valid body tissue taken from a human subject, which comprises detecting an altered concentration of a protein in the diagnostic sample, compared with a sample of a control human subject, the protein being selected from: Swiss Prot accession number: Protein name; P10909: Clusterin precursor; P00738: Haptoglobin precursor; P01009: Alpha-1-antitrypsin precursor; P01024: Complement C3 precursor; P01620: 1 g kappa chain V-III region; P01834: 1 g kappa chain C region P01842: 1 g lambda chain C regions; P01857: 1 g gamma-1 chain C region; P01859: Ig gamma-2 chain C region; P01876: 1 g alpha-1 chain C region P02647: Apolipoprotein A-I precursor; P02649: Apolipoprotein E precursor; P02652: Apolipoprotein A-II precursor; P02655: Apolipoprotein C-II precursor; P02656: Apolipoprotein C-II precursor P02671: Fibrinogen alpha/alpha-E chain precursor; P02763: Alpha-1-acid glycoprotein 1 precursor; P02766: Transthyretin precursor; P02768: Serum albumin precursor; P02787: Serotransferrin precursor; P04196: Histidine-rich glycoprotein precursor; P06727: Apolipoprotein A-IV precursor; P19652: Alpha-1-acid glycoprotein 2 precursor; P68871/P02042: Hemoglobin beta chain/Hemoglobin delta chain; P60709: Beta actin.

The invention discloses pseudovirions; a capsid protein of MS2 bacteriophage is wrapped with a DNA-protein complex of a detection sequence formed by series connection of three base fragments of influenza A virus, influenza B virus and beta-actin successively. The invention also provides a preparation method of the pseudovirions and an application of the pseudovirions as quality control products for detecting the influenza A virus and the hepatitis B virus. The preparation method of the pseudovirions is simple and is easy to operate; the obtained pseudovirus is high in purity, can be used as the quality control products in an influenza A virus and influenza B virus nucleic acid detection kit, and has the characteristics of no infectivity, good stability, ribonuclease resistance and the like.

The invention relates to a real-time fluorescence quantitative PCR (polymerase chain reaction) kit for quantitatively detecting TRECs and KRECs genes and application thereof. The kit comprises a PCR system based on nested PCR technology and a real-time fluorescence quantitative PCR system based on real-time fluorescence PCR technology, wherein the nested PCR system comprises forward and reverse primers for TRECs, KRECs and beta-actin genes; and the real-time fluorescence quantitative PCR system comprises forward and reverse primers and specific fluorescence probes for TRECs, KRECs and beta-actin genes. The kit can be used for quickly screening the T-cell level and B-cell level of a neonatal immune system, and has the advantages of high sensitivity, high stability and excellent reproducibility. The method is suitable for combined quantitative detection of TRECs and KRECs, can be used for screening functions of the neonatal immune system, and has practical clinical application value.

The invention belongs to the gene detecting technology in the clinical detecting technology in the bio-medical field and particularly relates to a kit for quickly detecting polymorphism of human VKORC1 and CYP2CP genes and a using method of the kit. The kit comprises three pairs of primers, three probes, six PNA sequences, 1 pair of beta-Actin interior label primers and one interior label probe, further comprises Mg<2+> PCR (polymerase chain reaction) buffer liquor, a dNTP mixture, Tag enzyme and ddH2O. The kit disclosed by the invention can be used for performing qualitative detection on polymorphic sites of the VKORC1 and CYP2C9 genes, performing two-tube PNA-PCR fluorescent amplification reaction according to an SNP site and performing result judgment according to the condition whether a two-tube fluorescent curve is formed or not without producing manual errors, so that the false positive rate and the false negative rate are low. The kit disclosed by the invention can easily realize high-flux detection and is capable of satisfying clinical use very well.

The present invention relates to a quantitative detection analysis method of human plasma DNA level. Said method includes the following steps: selecting artificially-synthetic exogenous DNA series whose extraction efficiency is identical to or similar to that of human plasma DNA, but they are non-homologous, selecting housekeeping gene beta actin as determination gene, inserting artificially-synthetic exogenous DNA into carrier pMD18T and placing it in the bacteria to make culture, making blue and white spot screening, colony PCR identification, enzyme-cutting into linearity, placing the above-mentioned material into plasma, adopting double fluorescent quantitative gene amplification, fluorescent groups are respectively FAM and HEX, extracting known exogenous positive plasmid recovery efficiency, using computation formula to make computation so as to obtain the quantity of plasma DNA.

The present inventors concerns vectors carrying a truncated chimeric CMV-chicken β-actin (smCBA) promoter in which the hybrid chicken β-actin/rabbit β-globin intron is greatly shortened, and their use to deliver to an operatively linked polynucleotide to host cells in vitro or in vivo, resulting in expression of the polynucleotide in the host cells. In one embodiment, the vector carrying the smCBA promoter is administered to the eye. In another embodiment, the vector carrying the smCBA promoter is a self-complementary adeno-associated virus (AAV). The AAV vector may be of any serotype (e.g., type 1, type 2, type 3, type 4, type 5, type 6, type 7, type 8, type 9, type 10). In another embodiment, a self-complementary vector carrying the smCBA promoter is administered to the eye. Another aspect of the invention concerns host cells carrying a vector of the invention. Another aspect of the invention concerns pharmaceutical composition comprising the vectors or host cells of the invention, and a pharmaceutically acceptable carrier.

The invention provides a methylation gene combination, primer and probe combination and kit for cervical cancer methylation detection and a using method of the kit, and belongs to the technical fieldof medical gene detection. Based on a real-time fluorescent PCR technology, specific methylation detection primers and probes in the promoter regions of FAM19A4, has-miR-124-2 and ZNF671 genes are designed and prepared into a PCR reaction solution to amplify a sample DNA after vulcanization, the quality of the sample is controlled by means of an internal reference gene beta-actin, and whether or not the sample is methylated is determined. Compared with the conventional method, the method has the advantages of fast speed, high flux and good sensitivity and specificity, and plays an important role in the early diagnosis and prognosis of cervical cancer.

Disclosed are methods and compositions for the selective manipulation of gene expression through the preparation of retroviral expression vectors for expressing antisense sequences, such as K-ras oncogene antisense sequences, or sequences encoding a desired product, such as wild type p53 sequences. Preferred retroviral vectors of the present invention incorporate the β-actin promoter in a reverse orientation with respect to retroviral transcription. Preferred antisense RNA constructs of the present invention employ the use of antisense intron DNA corresponding to distinct intron regions of the gene whose expression is targeted for down-regulation. In an exemplary embodiment, a human lung cancer cell line (NCI-H460a) with a homozygous spontaneous K-ras mutation was transfected with a recombinant plasmid that synthesizes a genomic segment of K-ras in antisense orientation. Translation of the mutated K-ras mRNA was specifically inhibited, whereas expression of H-ras and N-ras was unchanged. A three-fold growth inhibition occurred in H460a cells when expression of the mutated ras p21 protein was down-regulated by antisense RNA and cells remained viable. The growth of H460a tumors in nu/nu mice was substantially reduced by expressed K-ras antisense RNA.

The invention discloses a real-time fluorescent PCR method for testing the allergen genes of aquatic food, comprising the following steps: total RNA of samples is extracted; the allergen genes Par and TM of aquatic food, and internal standard gene Beta-actin are respectively tested by SYBR Green or TaqMan probe real-time fluorescent PCR technology; and result analysis is carried out to the tested samples according to the amplification kinetic curve and the Ct value. As the real-time fluorescent PCR technology is used for testing the allergen genes Par and TM of aquatic food, compared with other methods, the method has the advantages of high sensitivity, short testing time, available quantitative analysis, and the like, and can be used in the qualitative screening, quantitative analysis and confirmation identification of allergen genes in unknown species or mixed samples of aquatic food.

This patent discloses compositions and methods of use thereof to normalize the blood glucose levels of patients with type 2 diabetes. It relates particularly to a plasmid comprising a chicken beta actin promoter and enhancer; a modified GLP-1 (7-37) cDNA (pbetaGLP1), carrying a furin cleavage site, which is constructed and delivered into a cell for the expression of active GLP-1.

The invention relates to a human red cell ABO blood type antigen multi-PCR genotyping method and a kit. The human red cell ABO blood type antigen multi-PCR genotyping method is characterized in that multi-PCR is adopted; four pair of specific primers are designed; O, no-O, B and no-B are correspondingly amplified; beta-actin is treated as an internal reference, and on that basis, two multi-PCR reactions systems are constructed; and the ABO blood types of a sample can be primarily determined on the basis of amplified bands. According to the method, the multi-PCR method is guided into ABO bloodtype genotyping; and the SNP loci of O allele and B allele are utilized to realize the ABO blood type genotyping. With the adoption of the method, the times of PCR reaction per person in ABO antigen genotyping can be reduced; the detection labor and the agent cost can be decreased; the detection throughput is increased; and the time needed in detection of a large quantity of samples can be shortened.

The invention discloses an equine infectious anemia virus (EIAV) gene transfer vector, a constructed method and an application thereof. The vector of the invention comprises a CMV/R/U5 promoter, a 5' non-translated region homing sequence, a partial 5' gag gene coding region sequence, a central polypurine sequence, an Rev reaction element of EIAV, a CMVIE/chicken beta-actin promoter, a reporter gene, WPRE of WHBV, a polyclone locus, a poly (A) signal before EIAV 3'LTR, complete 3'LTR and partial sequence of eukaryon expression vector. The vector of the invention possesses common advantages of lentiviral vector, lacks auxiliary genes of all the wild-type virus, can carry one or a plurality of selected genes to transmit to target cells, can insert with target DNA sequence with large fragments and can lead the foreign genes and reporter genes to express at a high level in the cells.

The invention relates to the gene mutation relevant to the paralysis agitans and the detecting method, comprising: extracting DNA sample; designing primer; expanding with PCR; analyzing nucleic acid by means of dHPLC technology; testing the gene order of the sample which is dHPLC positive reaction to definite the genetype; carrying out beta-actin comparison for the sample of repeated extanding negative reaction to eliminate extron deletion mutation. The parkin gene mutation is in the codon promoter of the parkin gene, the second basic group in the exon1, ATG mutated to ACG; on the intersection point of thefifth introne and sixth extron in the exon6, AG mutated to AC; in the sixth extron, the 727th basic group, G mutated to A; in the exon9, the 1016th basic group, C mutated to T; in the position of ring finger intermediate region, in the Znf C6HC zinc region, GCG mutated to CGTC. By applying the gene mutation and the detection method, the detection for the mutation site of the parkin fene is high-effective and low-cost, and the diagnose to the potential PD patient can be made in an early stage.

The invention relates to the technical field of breast cancer diagnosis, and specifically discloses RNA (Ribonucleic Acid) circEPSTI1 (Epithelial-stromal Interaction 1) and application thereof in triple negative breast cancer. The application of the RNA circEPSTI1 in the triple negative breast cancer comprises the following steps: firstly, collecting a to-be-detected suspected triple negative breast cancer tissue sample, extracting total RNA, specifically and reversely transcribing the cyclic RNA circEPSTI1 (hsa_circRNA_000479) into cDNA (Complementary Deoxyribonucleic Acid) by using the total RNA as a template; carrying out real-time quantitative PCR (Polymerase Chain Reaction) amplification by using a specific PCR primer; using beta-actin as a reference gene, thus obtaining a relative quantitative deltaCT value of circEPSTI1; reminding that the circEPSTI1 is in positive expression when deltaCT is smaller than or equal to 5.52. According to the RNA circEPSTI1 and the application thereof in the triple negative breast cancer, disclosed by the invention, the RNA circEPSTI1 is applied to prognostic prediction of a triple negative breast cancer patient through relatively and quantitatively detecting the expression situation of the circEPSTI1 in the suspected triple negative breast cancer tissue sample.

The invention relates to a real-time fluorescent quantitative PCR (polymerase chain reaction) kit for one-step quantitative detection of TRECs and KRECs genes and its application. The kit comprises a real-time fluorescent quantitative PCR reaction system based on the real-time fluorescent PCR technique. The real-time fluorescent quantitative PCR reaction system comprises forward and reverse primers specific to TRECs, KRECs and beta-actin genes, and a specific fluorescent probe. The kit allows quick joint screening of neonatal immune system T-cell level and B-cell level, has high sensitivity and stability and provides excellent reproducibility, and this method is applicable to the joint quantitative detection of TRECs and KRECs and to functional screening of the neonatal immune system and is worthy of practical clinical application.

The present application disclosed a method for preparing a sterile transgenic fish, comprising constructing antisense RNA expression vector of salmon-type gonadotropin-releasing hormone, introducing the recombinant DNA fragment into carp oosperm by microinjection, and screening the sterile transgenic fish by Polymerase Chain Reaction and radioimmunoassay, wherein the expression vector comprising a promoter of carp beta actin (β-actin) gene, a complementary DNA fragment of antisense salmon-type gonadotropin-releasing hormone (sGnRH) gene from carp with 323 bp as a target gene comprising sGnRH decapeptide, the coding region of gonadotropin-releasing hormone associated peptide and 3′ non-coding sequence, and 3′ flanking sequence of grass carp growth hormone gene as a stop sequence. The method of the present invention is easy and convenient for operation which provides a basis for providing a technical platform of general applicability for solving the hereditary and ecological safety problems of transgenic fishes.

The invention discloses a method for evaluating developmental potential of an oocyte by utilizing the relative expression of GRIM-19 in a granulosa cell. When the relative expression of the GRIM-19 in the granulosa cell of the oocyte is 0.16-0.35, the obtained oocyte is judged to be high in developmental potential; when the relative expression of the GRIM-19 is 0-0.12, the obtained oocyte is judged to be low in developmental potential; a beta-actin gene is selected for internal reference. The method disclosed by the invention is a more objective, accurate and quantizable oocyte quality evaluation method, is noninvasive without repeatedly taking out an incubator for observation, so that the adverse environmental stimulation is reduced. Due to being quantizable, the method disclosed by the invention has a specific numerical range, is easy to operate and solves the problem that due to artificial subjective factors, the judgment standards are not unified.

The invention discloses a PCR technology-based quail sex identification method, and belongs to the technical field of biological detection identification. Two pairs of PCR primers used for PCR identification comprise a pair of micro-satellite primers and a pair of internal control gene (beta-actin) primers. The PCR identification method comprises the following steps: carrying out PCR amplification by adopting the quail sex identification PCR primers with the blood sample genome DNA of a young quail to be detected as a template, detecting the above obtained PCR amplification product by adopting agarose gel electrophoresis, judging the young quail to be detected as a male quail when the amplification product only has a 259 bp specific amplification band, and judging the young quail to be detected as a female quail when the amplification product has a 259 bp specific amplification band and a 114 bp specific amplification band. The method has the advantages of simplicity and convenience in operation, realization of sex discrimination in at the hatching time, rapidness in discrimination, accurate result, and avoiding of the disadvantages of long time, high breeding cost and high error rate of traditional methods.

The invention discloses a selection method of reference genes in quantitative real-time PCR analysis of jerusalem artichoke, and relates to the field of quantitative PCR. The method comprises the following steps: taking different tissues (radicles, immature stems, leaves, stem blocks and petals) of the jerusalem artichoke as materials, and carrying out expression analysis of the reference genes of18S ribosomal RNA gene (18S rRNA), transcription elongation factor gene (Ef-1a), actin gene (Actin and beta-actin), 3-glyceraldehyde phosphate dehydrogenase (GAPDH), 25S ribosomal RNA gene (25S rRNA)and poly-ubiquitin enzyme gene (UBQ)7 by using a q PCR technology; carrying out statistical assessment on the obtained data and analyzing expression change of all housekeeping genes by utilizing GeNorm and NormFinder software, so as to screen out relatively-stable genes as the reference genes of the jerusalem artichoke, which are used for studying the gene dosage changes of the jerusalem artichoke.

The invention relates to a primer pair for colorectal-cancer related gene Septin9 methylation detection. The primer pair comprises a Septin9 forward primer, a Septin9 reverse primer, a Septin9 detection probe, a beta-Actin forward primer, a beta-Actin reverse primer and a beta-Actin detection probe. The invention relates to a kit for colorectal-cancer related gene Septin9 methylation detection. The kit comprises PCR reaction liquid comprising the primers and the probes, and the PCR reaction liquid comprises the forward primers, the reverse primers, the detection probes, 10*PCR buffer, dNTP, nuclease-free water and Ex Taq enzyme. The invention also relates to a method for colorectal-cancer related gene Septin9 methylation detection. The kit and the detection method have the advantages of being accurate in detection result, high in detection flux, good in specificity and sensitivity, short in detection time, convenient to use and capable of effectively meeting the clinical requirements.